TY - JOUR
T1 - The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
JO - Eur J Cancer
PY - 2007/11/01
AU - Tappenden P
AU - Jones R
AU - Paisley S
AU - Carroll C
ED -
DO - DOI: 10.1016/j.ejca.2007.08.017
VL - 43
IS - 17
SP - 2487
EP - 2494
Y2 - 2025/08/13
ER -